Close

Form 4 SCICLONE PHARMACEUTICALS For: Aug 12 Filed by: Blobel Friedhelm

August 16, 2016 5:41 PM EDT
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
Blobel Friedhelm

(Last) (First) (Middle)
950 TOWER LANE, SUITE 900

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2016
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/12/2016   M   3,500 A $ 0 463,782 (1) D  
Common Stock 08/12/2016   M   5,000 A $ 0 468,782 D  
Common Stock 08/12/2016   M   50,000 A $ 0 518,782 D  
Common Stock 08/12/2016   F (2)   1,827 D $ 10.41 516,955 D  
Common Stock 08/12/2016   F (2)   26,090 D $ 10.41 490,865 D  
Common Stock 08/12/2016   F (2)   2,610 D $ 10.41 488,255 D  
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (3) (4) 08/12/2016   A   40,000     (5)   (5) Common Stock 40,000 $ 0 383,500 D  
Restricted Stock Unit (6) (4) 08/12/2016   M     3,500   (7)   (7) Common Stock 3,500 $ 0 380,000 D  
Restricted Stock Unit (6) (4) 08/12/2016   M     5,000   (8)   (8) Common Stock 5,000 $ 0 375,000 D  
Restricted Stock Unit (6) (4) 08/12/2016   M     50,000   (9)   (9) Common Stock 50,000 $ 0 325,000 D  
Explanation of Responses:
1. Includes 1,000 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2016.
2. Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units.
3. Granted under the Issuer's 2015 Equity Incentive Plan.
4. Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
5. Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017.
6. Granted under the Issuer's 2005 Equity Incentive Plan.
7. Vesting for such RSUs will occur 50% on February 20, 2015 and 50% on February 20, 2016, or on such later date thereafter as the Company's trading window opens if it is not open on either of such dates.
8. Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.
9. Vesting to be in three equal annual installments at the close of business on the first business day following December 31 of each of calendar year 2015, 2016, and 2017, provided that the Participant's service with the Company has not terminated prior to the applicable vesting time.
Friedhelm Blobel, Ph.D. 08/16/2016
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings